World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
101
Citations
50495
World Ranking
7835
National Ranking
4082

Overview

Oliver Sartor is affiliated with Tulane University in the United States and has a significant research presence in the field of Medicine, with a particular focus on Oncology and Cancer Research. Their scholarly contributions include substantial work related to prostate cancer diagnosis, treatment, and radiopharmaceutical applications.

Their research encompasses a variety of subfields within Medicine, notably:

  • Pulmonary and Respiratory Medicine
  • Radiology, Nuclear Medicine and Imaging
  • Oncology
  • Cancer Research
  • Molecular Biology

Sartor's main areas of research focus on topics such as:

  • Prostate Cancer Treatment and Research
  • Radiopharmaceutical Chemistry and Applications
  • Prostate Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • PARP inhibition in cancer therapy
  • Cancer Immunotherapy and Biomarkers
  • Cancer, Lipids, and Metabolism

Their frequently published work appears in several prominent journals, including:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Urology
  • International Journal of Radiation Oncology*Biology*Physics
  • Journal of Nuclear Medicine

Notable recent papers authored by Oliver Sartor include:

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer (2021, New England Journal of Medicine)
  • Olaparib for Metastatic Castration-Resistant Prostate Cancer (2020, New England Journal of Medicine)
  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer (2020, New England Journal of Medicine)
  • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019 (2020, European Urology)
  • Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019 (2020, Journal of Clinical Oncology)

Oliver Sartor frequently collaborates with other researchers, with frequent co-authors including:

  • Pedro C. Barata
  • Elisa M. Ledet
  • Karim Fizazi
  • Johann S. de Bono
  • Ellen Jaeger

Best Publications

  • Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

    Johann Sebastian De Bono;Stephane Oudard;Mustafa Ozguroglu;Steinbjørn Hansen

  • Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

    C. Parker;S. Nilsson;S. Nilsson;D. Heinrich;S. I. Helle

  • Olaparib for metastatic castration-resistant prostate cancer

    Johann de Bono;Joaquin Mateo;Karim Fizazi;Fred Saad

  • Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.

    Oliver Sartor;Johann de Bono;Kim N Chi;Karim Fizazi

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

    Glenn J. Bubley;Michael Carducci;William Dahut;Nancy Dawson

  • Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

    Kenneth R. Carson;Andrew M. Evens;Elizabeth A. Richey;Thomas M. Habermann

  • Prostate Specific Antigen Best Practice Statement: 2009 Update

    Kirsten L. Greene;Peter C. Albertsen;Richard J. Babaian;H. Ballentine Carter

  • Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer

    William U. Shipley;Wendy Seiferheld;Himanshu R. Lukka;Pierre P. Major

  • Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

    Oliver Sartor;Robert E Coleman;Sten Nilsson;Daniel Heinrich

  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

    Maha Hussain;Joaquin Mateo;Karim Fizazi;Fred Saad

  • A review of technology and policy deep decarbonization pathway options for making energy-intensive industry production consistent with the Paris Agreement

    Chris Bataille;Max Åhman;Karsten Neuhoff;Lars J. Nilsson

  • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

    Silke Gillessen;Gerhardt Attard;Tomasz M Beer;Himisha Beltran

  • Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer.

    C L Bennett;M R Ferreira;T C Davis;J Kaplan

  • Metastatic Prostate Cancer

    Oliver Sartor;Johann S. de Bono

  • Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial

    Peter Hoskin;Oliver Sartor;Joe M O'Sullivan;Dag Clement Johannessen

  • Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.

    Thomas Powles;Thomas Powles;Tibor Csőszi;Mustafa Özgüroğlu;Nobuaki Matsubara

  • Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy : the SPARC trial

    Cora N. Sternberg;Daniel P. Petrylak;Oliver Sartor;J. Alfred Witjes

  • Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline

    Ian M. Thompson;Ian M. Thompson;Richard K. Valicenti;Richard K. Valicenti;Peter Albertsen;Peter Albertsen;Brian J. Davis;Brian J. Davis

  • Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer.

    Oliver Sartor;Robert H Reid;Peter J Hoskin;Donald P Quick

Frequent Co-Authors

Chris Parker
Chris Parker Institute of Cancer Research
Celestia S. Higano
Celestia S. Higano University of Washington
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Neal D. Shore
Neal D. Shore Carolina Urologic Research Center
Charles L. Bennett
Charles L. Bennett Johns Hopkins University
Cora N. Sternberg
Cora N. Sternberg Cornell University
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Susan Halabi
Susan Halabi Duke University
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Robert E. Coleman
Robert E. Coleman University of Sheffield

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in a career in medicine but seeking flexible or alternative routes, online healthcare degrees offer a range of options. online adn programs for non nurses make it possible for those without nursing backgrounds to begin their journey toward becoming a registered nurse from the comfort of home.

If you’re interested in the administrative or technical side of healthcare, consider enrolling in one of the best online medical billing and coding schools. These programs teach essential skills needed for managing medical records, insurance claims, and coding—all key roles in any modern healthcare setting.

Some students may be concerned about challenging entry exams. Fortunately, there are nursing schools that don't require teas, making applications less stressful while maintaining quality education standards.

Finally, aspiring healthcare managers can fast-track their careers with accelerated healthcare administration degree online programs. These pathways prepare graduates to work in leadership and operations roles within hospitals, clinics, and wider healthcare systems.

Best Scientists Citing Oliver Sartor

Trending Scientists

Recently Published Articles